PE20061312A1 - Composiciones farmaceuticas que contienen camostato - Google Patents

Composiciones farmaceuticas que contienen camostato

Info

Publication number
PE20061312A1
PE20061312A1 PE2006000388A PE2006000388A PE20061312A1 PE 20061312 A1 PE20061312 A1 PE 20061312A1 PE 2006000388 A PE2006000388 A PE 2006000388A PE 2006000388 A PE2006000388 A PE 2006000388A PE 20061312 A1 PE20061312 A1 PE 20061312A1
Authority
PE
Peru
Prior art keywords
camostate
compositions containing
pharmaceutical compositions
camostat
excipients
Prior art date
Application number
PE2006000388A
Other languages
English (en)
Inventor
Henry Luke Danahay
David C Tully
Silvia Heuerding
Janet Catherine Maas
Jean-Louis Reber
Stephanie Monnier
Juergen Roettele
Dilraj Singh
Jennifer Leslie Harris
Darren Mark Legrand
Original Assignee
Novartis Ag
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Irm Llc filed Critical Novartis Ag
Publication of PE20061312A1 publication Critical patent/PE20061312A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN: A) UNA SAL DE CAMOSTATO SELECCIONADO ENTRE SUCCINATO ACIDO DE CAMOSTATO, HIPURATO DE CAMOSTATO, ACETATO DE CAMOSTATO, ADIPATO DE CAMOSTATO, ENTRE OTROS; B) EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES. DICHA COMPOSICION FARMACEUTICA ES DE FORMA LIOFILIZADA O DE NEBULIZADOR QUE ADEMAS COMPRENDE EXCIPIENTES ENMASCARADORES DE SABOR TALES COMO ASPARTAME, MENTOL Y POLIALCOHOLES, REGULADORES DE pH Y DE LA TONICIDAD, AGENTES QUELANTES, TENSOACTIVOS, ENTRE OTROS. LAS FORMULACIONES SON INHIBIDORES DE PROTEASA ACTIVADORA DE CANAL (CAP) UTILES EN EL TRATAMIENTO DE FIBROSIS QUISTICA Y ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA
PE2006000388A 2005-04-14 2006-04-12 Composiciones farmaceuticas que contienen camostato PE20061312A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0507577.5A GB0507577D0 (en) 2005-04-14 2005-04-14 Organic compounds

Publications (1)

Publication Number Publication Date
PE20061312A1 true PE20061312A1 (es) 2006-12-28

Family

ID=34611136

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000388A PE20061312A1 (es) 2005-04-14 2006-04-12 Composiciones farmaceuticas que contienen camostato

Country Status (19)

Country Link
US (2) US20090203777A1 (es)
EP (3) EP1874726B1 (es)
JP (1) JP2008537750A (es)
KR (1) KR20070118257A (es)
CN (1) CN101160284A (es)
AR (1) AR053217A1 (es)
AU (1) AU2006233691B2 (es)
BR (1) BRPI0610551A2 (es)
CA (1) CA2601990A1 (es)
ES (1) ES2388683T3 (es)
GB (1) GB0507577D0 (es)
GT (1) GT200600139A (es)
MX (1) MX2007012700A (es)
PE (1) PE20061312A1 (es)
PL (1) PL1874726T3 (es)
PT (1) PT1874726E (es)
RU (1) RU2007141768A (es)
TW (1) TW200720236A (es)
WO (1) WO2006108643A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016441D0 (en) * 2000-07-04 2000-08-23 Pharmagene Lab Limited Therapeutic method
US7951823B2 (en) 2006-05-23 2011-05-31 Irm Llc Compounds and compositions as channel activating protease inhibitors
RS51644B (en) * 2007-01-10 2011-10-31 Irm Llc. UNITS AND PREPARATIONS AS CHANNEL INHIBITORS ACTIVATING PROSTHESES
GB2445920A (en) * 2007-01-25 2008-07-30 Mucokinetica Ltd Amidino compounds for treatment of respiratory disease
EP2117537A1 (en) 2007-02-09 2009-11-18 Irm Llc Compounds and compositions as channel activating protease inhibitors
GB0808690D0 (en) * 2007-05-17 2008-06-18 Serentis Ltd Therapeutic use
EP2138178A1 (en) * 2008-06-28 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
SI2538925T1 (sl) * 2010-02-25 2016-04-29 Bristol-Myers Squibb Company Apiksaban formulacije
RU2657523C2 (ru) * 2011-11-03 2018-06-14 Олег Петрович Жирнов Фармацевтический аэрозольный состав ингибиторов протеаз с озон-сберегающим пропеллентом и его получение
JP2014074019A (ja) * 2012-09-11 2014-04-24 Daiichi Sankyo Healthcare Co Ltd 抗ロタウイルス剤
EP2970141B1 (en) 2013-03-15 2020-02-26 Verseon Corporation Halogenopyrazoles as inhibitors of thrombin
LT2968297T (lt) 2013-03-15 2019-01-10 Verseon Corporation Multipakeistieji aromatiniai junginiai kaip serino proteazės inhibitoriai
CA2960790A1 (en) 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
EP3261639B1 (en) 2015-02-27 2022-08-24 Verseon International Corporation Substituted pyrazole compounds as serine protease inhibitors
CA3171958A1 (en) * 2020-03-18 2021-09-23 Memorial Sloan Kettering Cancer Center Inhalational therapy for covid-19
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
IT202000014350A1 (it) * 2020-06-16 2021-12-16 Andrea Alimonti NUOVO APPROCCIO FARMACOLOGICO PER IL TRATTAMENTO DI SARS-CoV2 E VIRUS INFLUENZALI TRAMITE L’USO DI SPRAY NASALI
WO2022065860A1 (ko) * 2020-09-24 2022-03-31 충북대학교 산학협력단 나파모스타트 또는 카모스타트를 포함하는 흡입용 제제
KR102664833B1 (ko) * 2020-09-24 2024-05-14 충북대학교 산학협력단 나파모스타트 또는 카모스타트를 포함하는 흡입용 제제

Family Cites Families (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706229A1 (de) 1997-02-18 1998-08-20 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
GB1472700A (en) * 1974-11-01 1977-05-04 Ono Pharmaceutical Co Guanidinobehzoic acid derivatives and process for preparing the same
JPS57144224A (en) * 1981-03-02 1982-09-06 Mochida Pharmaceut Co Ltd Remedy for respiratory dieseases
CA1341029C (en) 1985-02-04 2000-06-20 Michael Kolb Peptidase inhibitors
JPS6235216A (ja) 1985-08-09 1987-02-16 Noritoshi Nakabachi 不均質物質層の層厚非破壊測定方法および装置
AU598750B2 (en) 1985-09-27 1990-07-05 Mitsubishi Chemical Corporation Phenylalanine derivative and proteinase inhibitor
US4990537A (en) * 1988-07-11 1991-02-05 Banyu Pharmaceutical Co., Ltd. Anti influenza agent
JPH02243624A (ja) * 1988-07-11 1990-09-27 Banyu Pharmaceut Co Ltd 抗ウイルス剤
JPH02289598A (ja) 1989-04-28 1990-11-29 Yamanouchi Pharmaceut Co Ltd Ｍｓ―１１４４物質
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
US5037819A (en) 1990-06-04 1991-08-06 Bristol-Myers Squibb Company Azetidin-2-one derivatives as serine protease inhibitors
US6060451A (en) 1990-06-15 2000-05-09 The National Research Council Of Canada Thrombin inhibitors based on the amino acid sequence of hirudin
GB9017694D0 (en) 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
IL99527A (en) 1990-09-28 1997-08-14 Lilly Co Eli Tripeptide antithrombotic agents
US5468727A (en) * 1990-12-13 1995-11-21 Board Of Regents, The University Of Texas System Methods of normalizing metabolic parameters in diabetics
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
DE4115468A1 (de) 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
JPH0525045A (ja) 1991-07-18 1993-02-02 Tanabe Seiyaku Co Ltd 経皮吸収製剤
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
JPH05213927A (ja) 1992-02-10 1993-08-24 Torii Yakuhin Kk 新規フランカルボン酸アミジノナフチルエステル誘導体およびその酸付加塩
TW223629B (es) 1992-03-06 1994-05-11 Hoffmann La Roche
WO1993018007A1 (en) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Novel carbostyril derivative
AU677776B2 (en) 1992-04-02 1997-05-08 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
WO1993019750A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic or inflammatory diseases
EP0636026B1 (en) 1992-04-02 2001-12-05 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
US5432178A (en) 1992-09-18 1995-07-11 Ono Pharmaceutical Co., Ltd. Amidinophenol derivatives
FR2701951B1 (fr) 1993-02-24 1995-06-09 Adir Nouveaux derives peptidiques de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CZ289930B6 (cs) 1993-03-12 2002-04-17 Axys Pharmaceuticals, Inc. Arylové a heteroarylové peptidové deriváty a farmaceutické prostředky je obsahující
JPH06340619A (ja) * 1993-05-03 1994-12-13 Bristol Myers Squibb Co グアニジニルまたはアミジニル置換メチルアミノ複素環トロンビン抑制剤
GB9322976D0 (en) 1993-11-08 1994-01-05 Pfizer Ltd Therapeutic agents
US5550139A (en) * 1994-01-03 1996-08-27 The Wichita State University Serine protease inhibitors
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
FR2721611B1 (fr) 1994-06-22 1996-09-27 Adir Nouveaux dérivés peptidiques de l'acide boronique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent .
JPH0820570A (ja) 1994-07-06 1996-01-23 Teikoku Chem Ind Corp Ltd アルファ置換プロピオン酸エステル化合物
JPH0820597A (ja) 1994-07-07 1996-01-23 Meiji Seika Kaisha Ltd トロンビン阻害作用を有する複素環カルボニル化合物
US5510369A (en) 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
KR0173034B1 (ko) 1995-04-28 1999-03-30 성재갑 선택적 트롬빈 억제제
JPH08333287A (ja) 1995-06-02 1996-12-17 Fuji Yakuhin Kogyo Kk 芳香環置換アルキルカルボン酸及びアルカノール誘導体とそれらを含有する抗血栓剤
US6211154B1 (en) 1995-06-07 2001-04-03 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US6022861A (en) 1995-06-07 2000-02-08 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5523308A (en) 1995-06-07 1996-06-04 Costanzo; Michael J. Peptidyl heterocycles useful in the treatment of thrombin related disorders
CA2224437A1 (en) 1995-06-27 1997-01-16 Merck & Co., Inc. Pyridinone-thrombin inhibitors
IT1277405B1 (it) 1995-08-01 1997-11-10 Menarini Farma Ind Derivati di lattami biciclici come inibitori della trombina
CA2236007A1 (en) 1995-10-31 1997-07-17 Gerald Floyd Smith Antithrombotic diamines
GB9522495D0 (en) 1995-11-02 1996-01-03 Pfizer Ltd Therapeutic agents
FR2745288B1 (fr) 1996-02-27 1998-04-17 Adir Nouveaux derives de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE341317T1 (de) * 1996-03-29 2006-10-15 Ortho Mcneil Pharm Inc Amidinohydrazone als protease-inhibitoren
KR20000005312A (ko) * 1996-04-10 2000-01-25 오노 야꾸힝 고교 가부시키가이샤 트립타아제 억제제 및 신규 구아니디노 유도체
JP3140790B2 (ja) 1996-04-23 2001-03-05 メルク エンド カンパニー インコーポレーテッド ピラジノン系トロンビン阻害薬
GB2312674A (en) * 1996-05-02 1997-11-05 Ciba Geigy Ag Tetrahydroquinoline inhibitors of trypsin and thrombin
JPH09309873A (ja) * 1996-05-22 1997-12-02 Jiyunsei Kagaku Kk メシル酸カモスタットの新規な製造法
US6201006B1 (en) 1996-05-31 2001-03-13 C & C Research Laboratories Aromatic amidine derivatives useful as selective thrombin inhibitors
GB9611461D0 (en) 1996-06-01 1996-08-07 Ciba Geigy Ag New compounds
NZ333696A (en) 1996-07-08 2000-06-23 Du Pont Pharm Co Amidinoindoles, amidinoazoles, and analogs thereof as inhibitors of trypsin like protease enzymes like thrombin and Xa factor
IL121474A0 (en) 1996-08-23 1998-02-08 Akzo Nobel Nv Thrombin inhibitors
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
TW499412B (en) 1996-11-26 2002-08-21 Dimensional Pharm Inc Aminoguanidines and alkoxyguanidines as protease inhibitors
EP0969840A4 (en) 1997-03-24 2001-02-28 Merck & Co Inc THROMBIN INHIBITORS
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
AU740447B2 (en) 1997-09-23 2001-11-01 Merck & Co., Inc. Thrombin inhibitors
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
FR2773804B1 (fr) 1998-01-19 2000-02-18 Sanofi Sa Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
ES2312210T3 (es) 1998-06-17 2009-02-16 N.V. Organon Composiciones antitromboticas.
BR9815931A (pt) 1998-06-30 2001-02-20 Dow Chemical Co Polióis poliméricos, um processo para sua produção, e espuma de poliuretanoobtida
DE19829964A1 (de) 1998-07-04 2000-01-05 Boehringer Ingelheim Pharma Benzimidazole, deren Herstellung und deren Verwendung als Arzneimittel
TWI248435B (en) 1998-07-04 2006-02-01 Boehringer Ingelheim Pharma Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions
AU758237B2 (en) 1998-09-28 2003-03-20 Merck & Co., Inc. Thrombin inhibitors
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
TR200102766T2 (tr) * 1999-01-27 2001-12-21 Ortho-Mcneil Pharmaceutical, Inc. Triptaz inhibitörü olarak kullanılan peptidil heterosiklik ketonlar
KR20000060566A (ko) 1999-03-17 2000-10-16 이경하 치환된 방향족 아미딘 유도체 및 이를 함유하는 의약조성물
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
ES2246233T3 (es) 1999-05-04 2006-02-16 Schering Corporation Derivados de piperidina utiles como antagonistas de ccr5.
BR0010304A (pt) 1999-05-04 2002-02-13 Schering Corp Derivados de piperazina úteis como antagonistas do ccr5
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
UA58636C2 (uk) 1999-06-04 2003-08-15 Мерк Енд Ко., Інк. Піразинонові інгібітори тромбіну, фармацевтична композиція, спосіб інгібування утворення тромбів у крові, спосіб лікування станів, пов'язаних із тромбоутворенням
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6294648B1 (en) * 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity
CA2381802C (en) 1999-08-21 2010-12-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of roflumilast and salmeterol
WO2001019809A1 (en) * 1999-09-14 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
GB9923710D0 (en) * 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
CA2391012A1 (en) 1999-11-23 2001-05-31 Merck & Co., Inc. Pyrazinone thrombin inhibitors
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
ATE268322T1 (de) * 1999-12-20 2004-06-15 Altana Pharma Ag Inhibitoren der tryptase
DE60011677T2 (de) * 1999-12-20 2005-07-14 Altana Pharma Ag Tryptase-inhibitoren
FR2806722B1 (fr) 2000-03-23 2002-05-17 Sanofi Synthelabo Derives de n-(heterocyclylbutyl) benzene-ou pyridine sulfonamide, leur preparation et leur application en therapeutique
WO2001072712A1 (en) 2000-03-24 2001-10-04 Cor Therapeutics, Inc. ISOQUINOLONE INHIBITORS OF FACTOR Xa
MXPA02010593A (es) 2000-04-25 2003-05-14 Abbott Lab Inhibidores de uroquinasa de naftamidina.
IL152140A0 (en) 2000-04-27 2003-05-29 Boehringer Ingelheim Pharma Novel, slow-acting betamimetics, a method for their production and their use as medicaments
AU2001266089A1 (en) * 2000-06-23 2002-01-02 Bayer Aktiengesellschaft Regulation of human prostasin-like serine protease
DE20122417U1 (de) 2000-06-27 2005-08-04 Laboratorios S.A.L.V.A.T., S.A., Esplugues De Llobregat Von Arylalkylaminen abgeleitete Carbamate
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
GB0016441D0 (en) * 2000-07-04 2000-08-23 Pharmagene Lab Limited Therapeutic method
WO2002006455A2 (en) * 2000-07-19 2002-01-24 Bayer Aktiengesellschaft Regulation of human airway trypsin protease-like enzyme
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
IL154175A0 (en) 2000-08-05 2003-07-31 Glaxo Group Ltd 17. beta.-carbothioate 17. alpha-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents
GB0021497D0 (en) * 2000-09-01 2000-10-18 Novartis Res Foundation Compounds and their use
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
IL156499A0 (en) 2000-12-22 2004-01-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
SI20743A (sl) 2000-12-22 2002-06-30 Univerza V Ljubljani, Novi trombinski inhibitorji
SK287414B6 (sk) 2000-12-28 2010-09-07 Laboratorios Almirall, S.A. Chinuklidínové deriváty a kompozície s ich obsahom
WO2002064140A1 (en) 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
DE60220887T2 (de) 2001-03-08 2008-02-28 Glaxo Group Ltd., Greenford Agonisten von beta-adrenorezeptoren
WO2002074732A2 (en) * 2001-03-15 2002-09-26 Altana Pharma Ag Tryptase-inhibitors
WO2002076933A1 (en) 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
AU2002253342B2 (en) 2001-04-30 2007-01-04 Glaxo Group Limited Novel anti-inflammatory androstane derivatives
ATE399174T1 (de) 2001-06-12 2008-07-15 Glaxo Group Ltd Neue anti inflammatorische 17.alpha.- heterozyklische ester von 17.beta.-carbothioat androstan derivativen
EP1578910A4 (en) 2001-06-21 2008-06-04 Verenium Corp NITRILASES
CA2458534C (en) 2001-09-14 2011-11-01 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
JP2005512974A (ja) 2001-10-17 2005-05-12 ユ セ ベ ソシエテ アノニム キヌクリジン誘導体、その調製方法、及びｍ２及び／又はｍ３ムスカリン受容体阻害剤としてのその使用
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
AU2002356759A1 (en) 2001-12-01 2003-06-17 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
MXPA04006206A (es) 2001-12-20 2004-12-06 S A L V A T Lab Sa Derivados de 1-alquil-azoniabiciclo(2.2.2(octano carbamato y su uso como antagonistas del receptor musrcarinico.
WO2003072592A1 (en) 2002-01-15 2003-09-04 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
WO2003062259A2 (en) 2002-01-21 2003-07-31 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
JP2003246730A (ja) * 2002-02-22 2003-09-02 Torii Yakuhin Kk トリプターゼ阻害剤
JP2003252754A (ja) * 2002-02-26 2003-09-10 Teijin Ltd Ａｓｔ阻害剤
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
EP1490317A1 (en) 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DK1490062T3 (da) 2002-03-26 2008-04-28 Boehringer Ingelheim Pharma Glukokortikoidmimetika, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger og anvendelser deraf
WO2003086294A2 (en) 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ATE381535T1 (de) 2002-04-25 2008-01-15 Glaxo Group Ltd Phenethanolaminderivate
US6747043B2 (en) 2002-05-28 2004-06-08 Theravance, Inc. Alkoxy aryl β2 adrenergic receptor agonists
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
ES2201907B1 (es) 2002-05-29 2005-06-01 Almirall Prodesfarma, S.A. Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
DE10227269A1 (de) 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
EP1517895B1 (en) 2002-06-25 2007-03-14 Merck Frosst Canada Ltd. 8-(biaryl) quinoline pde4 inhibitors
EP1519922A1 (en) 2002-07-02 2005-04-06 Merck Frosst Canada & Co. Di-aryl-substituted ethane pyridone pde4 inhibitors
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
EP1521733B1 (en) 2002-07-08 2014-08-20 Pfizer Products Inc. Modulators of the glucocorticoid receptor
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
PL373597A1 (en) 2002-08-10 2005-09-05 Altana Pharma Ag Piperidine-n-oxide-derivatives
PL372926A1 (en) 2002-08-10 2005-08-08 Altana Pharma Ag Piperidine-pyridazones and phthalazones as pde4 inhibitors
WO2004018449A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
JP2005538138A (ja) 2002-08-10 2005-12-15 アルタナ　ファルマ　アクチエンゲゼルシャフト Ｐｄｅ４インヒビターとしてのピリダジノン誘導体
AU2003253408A1 (en) 2002-08-17 2004-03-11 Nycomed Gmbh Novel phenanthridines
US20060113968A1 (en) 2002-08-17 2006-06-01 Altana Pharma Ag Novel benzonaphthyridines
US6858627B2 (en) 2002-08-21 2005-02-22 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
ATE423769T1 (de) 2002-08-23 2009-03-15 Ranbaxy Lab Ltd Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
WO2004019945A1 (en) 2002-08-29 2004-03-11 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
AU2003255493B8 (en) 2002-08-29 2009-03-26 Takeda Gmbh 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors
BR0313923A (pt) 2002-08-29 2005-07-12 Boehringer Ingelheim Pharma Derivados de 3-(sulfonamidoetil)-indol para uso como miméticos de glicocorticóide no tratamento de doenças inflamatórias, alérgicas e proliferativas
JP4601426B2 (ja) * 2002-09-06 2010-12-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体成分ｃ５に対する抗体を使用する喘息の処置の方法
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
MXPA05002644A (es) * 2002-09-10 2005-09-20 Bayer Healthcare Ag Derivados de pirimidinona como agentes terapeuticos contra procesos de remodelacion, isquemicos e inflamatorios agudos y cronicos.
CN1688577A (zh) 2002-09-18 2005-10-26 小野药品工业株式会社 三氮杂螺[5.5]十一烷衍生物及以它为活性成分的药物
JP2006096662A (ja) 2002-09-18 2006-04-13 Sumitomo Pharmaceut Co Ltd 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤
JP2004107299A (ja) 2002-09-20 2004-04-08 Japan Energy Corp 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤
JP4520309B2 (ja) 2002-09-20 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション 選択的糖質コルチコイド受容体調節剤としてのオクタヒドロ−２−Ｈ−ナフト［１，２−ｆ］インドール−４−カルボキサミド誘導体
DE10246374A1 (de) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1440966A1 (en) 2003-01-10 2004-07-28 Pfizer Limited Indole derivatives useful for the treatment of diseases
MXPA05003866A (es) 2002-10-11 2005-06-22 Pfizer Derivados de indol como agonistas beta-2.
WO2004037807A2 (en) 2002-10-22 2004-05-06 Glaxo Group Limited Medicinal arylethanolamine compounds
WO2004037805A1 (en) 2002-10-23 2004-05-06 Glenmark Pharmaceuticals Ltd. Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
PT1556342E (pt) 2002-10-28 2008-04-28 Glaxo Group Ltd Derivado de fenetanolamina para o tratamento de doenças respiratórias
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE10253220A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10253426B4 (de) 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
JP2004189659A (ja) * 2002-12-10 2004-07-08 Ono Pharmaceut Co Ltd 好中球エラスターゼ阻害剤を有効成分とする吸入剤
DE10261874A1 (de) 2002-12-20 2004-07-08 Schering Ag Nichtsteroidale Entzündungshemmer
EP1587818A4 (en) 2003-01-21 2010-10-13 Merck Sharp & Dohme 17-CARBAMOYLOXY CORTISOL DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
US7951823B2 (en) * 2006-05-23 2011-05-31 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP2019837B1 (en) * 2006-05-23 2011-03-23 Irm Llc Compounds and compositions as channel activating protease inhibitors

Also Published As

Publication number Publication date
US20120208882A1 (en) 2012-08-16
MX2007012700A (es) 2008-01-11
ES2388683T3 (es) 2012-10-17
EP2305639A3 (en) 2011-06-29
WO2006108643A2 (en) 2006-10-19
CA2601990A1 (en) 2006-10-19
AU2006233691A1 (en) 2006-10-19
EP1874726B1 (en) 2012-05-16
BRPI0610551A2 (pt) 2010-07-06
EP1874726A2 (en) 2008-01-09
GT200600139A (es) 2006-11-24
GB0507577D0 (en) 2005-05-18
AR053217A1 (es) 2007-04-25
WO2006108643A3 (en) 2007-04-26
EP2253612A1 (en) 2010-11-24
PT1874726E (pt) 2012-08-16
TW200720236A (en) 2007-06-01
CN101160284A (zh) 2008-04-09
JP2008537750A (ja) 2008-09-25
EP2305639A2 (en) 2011-04-06
US20090203777A1 (en) 2009-08-13
RU2007141768A (ru) 2009-05-20
AU2006233691B2 (en) 2011-05-26
PL1874726T3 (pl) 2012-10-31
KR20070118257A (ko) 2007-12-14

Similar Documents

Publication Publication Date Title
PE20061312A1 (es) Composiciones farmaceuticas que contienen camostato
PE20080121A1 (es) Metodos para reducir la aglomeracion de proteina
US9011941B2 (en) Combined allergy treatment and anti-drying compositions and related methods
US4668513A (en) Method for combating snoring
BRPI0619475B8 (pt) Composições farmacêuticas na forma de lipossomas compreendendo ciclosporina a, seu método de preparo e usos
CA2447924A1 (en) Olopatadine formulations for topical administration
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
WO2005115406A3 (en) 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
WO2006100075A3 (en) Use of an artificial sweetener to enhance absorption of nicotine
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
ECSP066327A (es) Composición de fexofenadina y proceso para prepararla
AR052062A1 (es) Composicion y metodo para tratar el asma
ATE398441T1 (de) Octenidinhaltige lutschtabletten gegen entzündliche erkrankungen des mund- und rachenraums
NO20072864L (no) En transmukosal veterinaersammensetning som omfatter detomidin
PE20030950A1 (es) Comprimido masticable con sabor agradable
PE20070828A1 (es) Composicion farmaceutica que contiene una sal de glicopirronio
NO20054662L (no) Farmasoytisk sammensetning omfattende 5-metyl-2-2'-(klor-6'-fluoranilin)fenyleddiksyre
RS53689B1 (en) LIQUID FORMULATION OF DEFERIPRON WITH FAVORABLE TASTE
AR064269A1 (es) Formulaciones inhalantes de bisfosfonato y metodos para su utilizacion
RU2008105323A (ru) Консервирующая композиция для офтальмологического применения
WO2007008778A3 (en) Formulations for enhanced mucosal delivery of pyy
CL2022000118A1 (es) Formulaciones orales de edaravone y método de fabricación de las mismas.
AR033151A1 (es) Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
ECSP044979A (es) Uso de bibn4096 en combinación con otros fármacos antimigrañosos para el tratamiento de migraña
PE20041022A1 (es) Formulaciones farmaceuticas que comprenden un nuevo agente enmascarante de la amargura

Legal Events

Date Code Title Description
FC Refusal